AorTech (AOR.L) 63.5p �9.3m
AGM Statement from the medical device development company and licensor of the world class bio-stable polymer, Elast-EonTM .
"Having recently completed a very successful fundraising, which was oversubscribed, AorTech is in the process of transitioning from a company which was focused on licensing its world class polymer technology to a medical device development business building upon the unique properties of the Elast-EonTM material.
Since completing the fundraising in June 2018, AorTech has engaged with a number of partners to accelerate the commercialisation of its device portfolio. Each of the partners has made good progress in their respective areas. On the heart valve project, technology transfer has been completed with Vascular Flow Technologies Limited which is now actively engaged with John Ely, who joined the Company as a non-executive Director on 11 June 2018, on design optimisation